General description
一种有效的、选择性FGFR抑制剂,作用于FGFR1/2/3,IC50为0.9 nM、1.4nM和1nM。
Infigratinib is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death.
Infigratinib是泛FGFR激酶抑制剂,是具有潜在抗血管生成和抗肿瘤活性的人成纤维细胞生长因子受体(FGFR)的口服生物利用泛抑制剂。 pan FGFR激酶抑制剂BGJ398与FGFR选择性结合并抑制其活性,这可能导致抑制肿瘤血管生成和肿瘤细胞增殖,并诱导肿瘤细胞死亡。
Properties
Iupac Name: | N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-{6-[4-(4-ethyl-1-piperazinyl)anilino]-4-pyrimidinyl}-N-methylurea |
Inchi Code | 1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31) |
Inchi Key | QADPYRIHXKWUSV-UHFFFAOYSA-N |
安全信息